Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TTX.AX
SellTetratherix Limited · Healthcare · Australia · $237M · Avg Vol: $138K/d
COMPANY DESCRIPTION
Tetratherix Limited is an Australian biotechnology company specializing in the development of advanced regenerative medical devices and biomaterials. The company's proprietary polymer technology, TetraMatrix, acts as a scaffold to promote rapid tissue regeneration and bone healing. Tetratherix occupies a highly specialized niche, targeting global orthopedic and wound care markets with its biocompatible, bioresorbable solutions.
FINANCIAL SUMMARY (AUD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 8.8M | 20.8M | — |
| EPS (AUD) | -0.08 | -0.09 | -0.36 | — | -0.18 | -0.18 | -0.15 | — |
| Shares | 50.3M | 50.3M | 50.3M | 0.0% | 53.1M | — | — | — |
| Debt | — | — | 2.0M | — | 11.0M | — | — | — |
| Equity | 0 | 0 | 27.2M | — | — | — | — | — |
| Op CF | -2.5M | -4.5M | -2.7M | — | -2.4M | — | — | — |
| Inv CF | -5.0K | -36.0K | -0.6M | — | — | — | — | — |
| Fin CF | 0.6M | 2.4M | 32.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TTX.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TTX.AX | Tetratherix Limited(you) | $237M | 34 | Sell |
| KZIA | Kazia Therapeutics Limited | $151M | 36 | Hold |
| SPL.AX | Starpharma Holdings Limited | $252M | 50 | Hold |
| ATH.AX | Alterity Therapeutics Limited | $80M | 28 | Sell |
| RAC.AX | Racura Oncology Ltd | $295M | 11 | Strong Sell |
| OCC.AX | Orthocell Limited | $151M | 14 | Strong Sell |
| ACW.AX | Actinogen Medical Limited | $117M | 18 | Strong Sell |
| ILA.AX | Island Pharmaceuticals Limited | $99M | 19 | Strong Sell |
| NYR.AX | Nyrada Inc. | $134M | 13 | Strong Sell |
| ATX.AX | Amplia Therapeutics Limited | $55M | 30 | Sell |
Peer medians: ROE -23.0% · P/E 35.3x · Gross margin 60.5%